RxDoctor Payments Data

Nghia Nguyen, MD

Internal Medicine · Houston, TXNPI 1922042977

Payments from drug & device makers

$1,487in general payments, 2019–2025

Across 55 payments — averaging $27.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$493
  • Optinose US, Inc.$172
  • Bayer$157
  • Astellas Pharma US Inc$107
  • Regeneron Healthcare Solutions, Inc.$85
  • Takeda Pharmaceuticals U.S.A., Inc.$80
  • plus $393 from 12 others

What the payments were for

  • Food & beverage$1,37392%
  • Education$1148%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,487 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$78,137
Medicare patients
158
Services billed
800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin492$733,032
FarxigaDapagliflozin Propanediol569$549,500
VascepaIcosapent Ethyl1,040$533,300
TradjentaLinagliptin342$474,219
LinzessLinaclotide414$352,736
VemlidyTenofovir Alafenamide222$319,433
JanuviaSitagliptin Phosphate203$268,987
ProliaDenosumab141$244,927
OzempicSemaglutide158$208,907
TrulicityDulaglutide158$190,576
CreonLipase/Protease/Amylase121$163,633
Trelegy ElliptaFluticasone/Umeclidin/Vilanter199$141,109
MyrbetriqMirabegron127$118,260
OtezlaApremilast21$100,635
RybelsusSemaglutide54$83,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$493$593,775628 claims
AmgenProlia, Otezla$22$345,562162 claims
GileadVemlidy$23$319,433222 claims
GSKTrelegy Ellipta, Breo Ellipta$77$175,301267 claims
Astellas Pharma US IncMyrbetriq$107$118,260127 claims
PfizerEliquis, Lyrica$18$88,00278 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →